Type I interferons have been suspected for decades to have a crucial role in the
pathogenesis of systemic lupus erythematosus (SLE). Evidence has now overturned several …

Kidney involvement in patients with systemic lupus erythematosus—lupus nephritis (LN)—is
one of the most important and common clinical manifestations of this disease and occurs in …

Plasmacytoid dendritic cells (pDCs) represent a unique cell type within the innate immune
system. Their defining property is the recognition of pathogen-derived nucleic acids through …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of
clinical manifestations and a relapsing-remitting course. New data regarding pathogenic …

Treatment of systemic lupus erythematosus (SLE) currently employs agents with relatively
unselective immunosuppressive properties. However, two target-specific biological drugs …

Background Systemic lupus erythematosus (SLE) is heterogeneous in organ involvement
and disease severity, presenting a broad clinical phenotype. Systemic type I interferon (IFN) …

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with systemic
clinical manifestations including, but not limited to, rash, inflammatory arthritis, serositis …

Type I interferons (IFNs) have recently received a lot of attention with the elucidation of the
pathogenesis of systemic lupus erythematosus (SLE). Type I IFNs are associated with many …

The discovery of interferon in the 1950s represents much more than the identification of the
first cytokine and the key mediator of antiviral host defense. Defining the molecular nature …

Objectives To investigate the expression of type I IFN (IFN-I) and neutrophil transcripts in
kidney tissue from patients with different classes of LN and their association with distinct …